AARS2
Alanine--tRNA ligase, mitochondrial
Also known as: AARSL, bA444E17.1, KIAA1270, SYAM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5JTZ9
- Gene
- AARS2
- Ensembl
- ENSG00000124608
- Chromosome
- 6
- Canonical length
- 985 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Mitochondria
OverviewNCBI Gene
The protein encoded by this gene belongs to the class-II aminoacyl-tRNA synthetase family. Aminoacyl-tRNA synthetases play critical roles in mRNA translation by charging tRNAs with their cognate amino acids. The encoded protein is a mitochondrial enzyme that specifically aminoacylates alanyl-tRNA. Mutations in this gene are a cause of combined oxidative phosphorylation deficiency 8. [provided by RefSeq, Dec 2011]
Canonical amino-acid sequenceUniProt
985 residues, UniProt reviewed canonical sequence.
>Q5JTZ9|AARS2
1 MAASVAAAAR RLRRAIRRSP AWRGLSHRPL SSEPPAAKAS AVRAAFLNFF RDRHGHRLVP
61 SASVRPRGDP SLLFVNAGMN QFKPIFLGTV DPRSEMAGFR RVANSQKCVR AGGHHNDLED
121 VGRDLSHHTF FEMLGNWAFG GEYFKEEACN MAWELLTQVY GIPEERLWIS YFDGDPKAGL
181 DPDLETRDIW LSLGVPASRV LSFGPQENFW EMGDTGPCGP CTEIHYDLAG GVGAPQLVEL
241 WNLVFMQHNR EADGSLQPLP QRHVDTGMGL ERLVAVLQGK HSTYDTDLFS PLLNAIQQGC
301 RAPPYLGRVG VADEGRTDTA YRVVADHIRT LSVCISDGIF PGMSGPPLVL RRILRRAVRF
361 SMEILKAPPG FLGSLVPVVV ETLGDAYPEL QRNSAQIANL VSEDEAAFLA SLERGRRIID
421 RTLRTLGPSD MFPAEVAWSL SLCGDLGLPL DMVELMLEEK GVQLDSAGLE RLAQEEAQHR
481 ARQAEPVQKQ GLWLDVHALG ELQRQGVPPT DDSPKYNYSL RPSGSYEFGT CEAQVLQLYT
541 EDGTAVASVG KGQRCGLLLD RTNFYAEQGG QASDRGYLVR AGQEDVLFPV ARAQVCGGFI
601 LHEAVAPECL RLGDQVQLHV DEAWRLGCMA KHTATHLLNW ALRQTLGPGT EQQGSHLNPE
661 QLRLDVTTQT PLTPEQLRAV ENTVQEAVGQ DEAVYMEEVP LALTAQVPGL RSLDEVYPDP
721 VRVVSVGVPV AHALDPASQA ALQTSVELCC GTHLLRTGAV GDLVIIGDRQ LSKGTTRLLA
781 VTGEQAQQAR ELGQSLAQEV KAATERLSLG SRDVAEALRL SKDIGRLIEA VETAVMPQWQ
841 RRELLATVKM LQRRANTAIR KLQMGQAAKK TQELLERHSK GPLIVDTVSA ESLSVLVKVV
901 RQLCEQAPST SVLLLSPQPM GKVLCACQVA QGAMPTFTAE AWALAVCSHM GGKAWGSRVV
961 AQGTGSTTDL EAALSIAQTY ALSQLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AARS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 9.4 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 9.4 nTPM
- esophagus: 8.3 nTPM
- ovary: 7.5 nTPM
- small intestine: 7.4 nTPM
- cervix: 7.3 nTPM
- cerebral cortex: 7.1 nTPM
Single-cell type
- tuft cells: 23 nCPM
- gonadotrophs: 16 nCPM
- paneth cells: 16 nCPM
- retinal amacrine cells: 15 nCPM
- fibro-adipogenic progenitors: 14 nCPM
- enterocytes: 14 nCPM
Immune cell
- naive B-cell: 2.9 nTPM
- basophil: 2.1 nTPM
- MAIT T-cell: 2.1 nTPM
- memory CD4 T-cell: 1.9 nTPM
- NK-cell: 1.9 nTPM
- naive CD4 T-cell: 1.8 nTPM
Brain region
- cerebellum: 20 nTPM
- choroid plexus: 14 nTPM
- cerebral cortex: 14 nTPM
- amygdala: 14 nTPM
- white matter: 14 nTPM
- pons: 14 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AARS2.
Disease | AllUniProt
Conditions AARS2 is implicated in, by any mechanism.
- Combined oxidative phosphorylation deficiency 8 (COXPD8) MIM:614096
- Leukoencephalopathy, progressive, with ovarian failure (LKENP) MIM:615889
Disease | GeneticClinVar
72 pathogenic / likely-pathogenic of 719 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Combined oxidative phosphorylation defect type 8
- Leukoencephalopathy, progressive, with ovarian failure
- AARS2-related disorder
- Inborn genetic diseases
- Cardiovascular phenotype
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.84
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.07
- DepMap mean gene effect
- -0.46
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of cGAS/STING signaling pathway
- mitochondrial alanyl-tRNA aminoacylation
Molecular functions
- alanine-tRNA ligase activity
- aminoacyl-tRNA deacylase activity
- ATP binding
- peptide lactyltransferase (ATP-dependent) activity
- tRNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Alanine-tRNA ligase, class IIc
- Translation protein, beta-barrel domain superfamily
- Threonyl/alanyl tRNA synthetase, SAD
- Alanine-tRNA ligase, class IIc, anti-codon-binding domain superfamily
- Threonyl/alanyl tRNA synthetase, class II-like, putative editing domain superfamily
- Alanyl-tRNA synthetase, class IIc, N-terminal
- Alanyl-tRNA synthetase, class IIc, core domain
- Alanine-tRNA ligase, eukaryota/bacteria
- Class II Aminoacyl-tRNA synthetase/Biotinyl protein ligase (BPL) and lipoyl protein ligase (LPL)
- Alanine--tRNA ligase
- tRNA synthetases class II (A)
- Threonyl and Alanyl tRNA synthetase second additional domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AARS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AARS2 as an antibody target. Whether an autoantibody or antibody against AARS2 could matter depends on whether native AARS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AARS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AARS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...